In an exploratory trial treating “long COVID”
Post# of 148187
(Total Views: 572)
Posted On: 03/08/2024 7:46:34 AM
Re: KenChowder #141682
Quote:
In an exploratory trial treating “long COVID” with the CCR5-binding antibody leronlimab, we observed significantly increased blood cell surface CCR5 in treated symptomatic responders but not in nonresponders or placebo-treated participants. These findings suggest an unexpected mechanism of abnormal immune downmodulation in some persons that is normalized by leronlimab.
I'm impatiently waiting for the peer reviewed journal article on long covid. I would bet my bottom dollar that the increase in CCR5 correlates to an increase in CD4 T-cells.
(10)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼